ContraBand: the only heart failure medical device that is placed outside the heart

Project Information

Contraband

Grant agreement ID: 190178748

DOI 10.3030/190178748

EC signature date 28 November 2022

Start date 1 December 2022

End date 30 November 2024

Funded under

• The European Innovation Council (EIC)

Total cost € 3 850 718,75

EU contribution € 2 499 999,00

Coordinated by

RESTORE MEDICAL LTD
Israel

Project description

New device restores heart function in patients with congestive heart failure

Congestive heart failure (CHF) is a serious condition that affects millions of people worldwide, causing significant healthcare costs and reducing their quality of life. With this in mind, the EU-funded Contraband project aims to address this issue with an implantable device that can restore heart function in patients with left ventricle failure. One of the major advantages is its built-in fail-safe mechanism, which ensures full reversibility of functionality. Additionally, the device’s proprietary stent within-a-stent design and transcatheter delivery system make it incredibly easy to use, while its full clinical flexibility allows it to be used in conjunction with other CHF devices and pharmacotherapies. The project plans to introduce the device into European clinical routines by 2024.

Objective

Worldwide 26 million people suffer from Congestive Heart Failure (CHF), a chronic condition that worsens with time and leads to staggering healthcare costs and a significant reduction of quality of life. ContraBand is an implantable device aiming to restore heart function in patient suffering from left ventricle failure. ContraBand’s benefits include built-in fail-safe for full reversibility of functionality, tremendous ease of use due to its proprietary stеnt-within-a-stеnt design and transcatheter delivery system, and full clinical flexibility to be compatible with pharmacotherapies and other CHF devices. In the project, we will finalise clinical development and introduce ContraBand into clinical routines in Europe. We expect to launch ContraBand in 2024, generate €15M in revenues in 2025 and €60M in 2026. Before market launch, we will create >95 jobs at the company in strategic locations in Europe.

Fields of science

• medical and health sciences › clinical medicine › cardiology

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme

Topic(s)

• HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open

Call for proposal

HORIZON-EIC-2022-ACCELERATOR-01

Funding Scheme

EIC-ACC - EIC-ACC

Coordinator

RESTORE MEDICAL LTD

• Net EU contribution: € 2 499 999,00
• Address: 6 YEHNONATAN NETANYAHU ; 6037604 OR YEHUDA ; Israel
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Activity type
  Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 3 850 718,75